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A Calcineurin-Dependent Transcriptional
Pathway for Cardiac Hypertrophy
approximately half a million individuals are diagnosed
with heart failure each year, with a mortality rate ap-
proaching 50%.
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Numerous studies have implicated intracellular Ca21Fort Worth, Texas 76107
as a signal for cardiac hypertrophy. In response to myo-‖Parke-Davis
cyte stretch or increased loads on working heart prepa-2800 Plymouth Road
rations, intracellular Ca21 concentrations increase (Mar-Ann Arbor, Michigan 48105
ban et al., 1987; Bustamante et al., 1991; Hongo et al.,
1995), consistent with a role of Ca21 in coordinating
physiologic responses with enhanced cardiac output. ASummary
variety of humoral factors, including angiotensin II
(AngII), phenylephrine (PE), and endothelin-1 (ET-1),In response to numerous pathologic stimuli, the myo-
which induce the hypertrophic response in cardiomyo-cardium undergoes a hypertrophic response charac-
cytes (Karliner et al., 1990; Sadoshima and Izumo, 1993;terized by increased myocardial cell size and activation
Sadoshima et al., 1993; Leite et al., 1994), also shareof fetal cardiac genes. We show that cardiac hypertro-
the ability to elevate intracellular Ca21 concentrations.phy is induced by thecalcium-dependent phosphatase
Hypertrophic stimuli result in reprogramming of genecalcineurin, which dephosphorylates the transcription
expression in the adult myocardium, such that genesfactor NF-AT3, enabling it to translocate to the nu-
encoding fetal protein isoforms like b-myosin heavycleus. NF-AT3 interacts with the cardiac zinc finger
chain (MHC) and a-skeletal actin are up-regulated,transcription factor GATA4, resulting in synergistic ac-
whereas the corresponding adult isoforms, a-MHC andtivation of cardiac transcription. Transgenic mice that
a-cardiac actin, are down-regulated. The natriuretic
express activated forms of calcineurin or NF-AT3 in
peptides, atrial natriuretic factor (ANF), and b-type natri-
the heart develop cardiac hypertrophy and heart fail-
uretic peptide (BNP), which decrease blood pressure by
ure that mimic human heart disease. Pharmacologic vasodilation and natriuresis, are also rapidly up-regu-
inhibition of calcineurin activity blocks hypertrophy in lated in the heart in response to hypertrophic signals
vivo and in vitro. These results define a novel hypertro- (reviewed in Komuro and Yazaki, 1993). The mecha-
phic signaling pathway and suggest pharmacologic
nisms involved in coordinately regulating these cardiac
approaches to prevent cardiac hypertrophy and heart genes during hypertrophy are unknown, although bind-
failure. ing sites for several transcription factors, including se-
rum response factor (SRF), TEF-1, AP-1, and Sp1, are
Introduction important for activation of fetal cardiac genes in re-
sponse to hypertrophy (Sadoshima and Izumo, 1993;
Cardiachypertrophy isan adaptive response of the heart Sadoshima et al., 1993; Kariya et al., 1994; Karns et al.,
to virtually all forms of cardiac disease, including those 1995; Kovacic-Milivojevic et al.,1996). Most recently, the
arising from hypertension, mechanical load, myocardial cardiac-restricted zinc finger transcription factorGATA4
infarction, cardiac arrhythmias, endocrine disorders, and has also been shown to be required for transcriptional
genetic mutations in cardiac contractile protein genes. activation of the genes for Ang II type 1a receptor and
While the hypertrophic response is initially a compen- b-MHC during hypertrophy (Herzig et al., 1997; Hase-
satory mechanism that augments cardiac output, sus- gawa et al., 1997; reviewed in Molkentin and Olson,
tained hypertrophy can lead to dilated cardiomyopathy, 1997).
heart failure, and sudden death. In the United States, A number of intracellular signaling pathways have
been implicated in transduction of hypertrophic stimuli.
For example, occupancy of the cell surface receptors# To whom correspondence should be addressed.
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for AngII, PE, and ET-1 leads to activation of phospholi-
pase C, resulting in the production of diacylglycerol and
inositol triphosphate, which in turn results in mobiliza-
tion of intracellular Ca21 and activation of protein kinase
C (PKC) (Sadoshima and Izumo, 1993; Yamazaki et al.,
1996; Zou et al., 1996). There is also evidence that the
Ras and mitogen-activated protein (MAP) kinase path-
ways are transducers of hypertrophic signals (Thorburn
et al., 1993; reviewed in Force et al., 1996). The extent to
which these signaling pathways are coordinated during
cardiac hypertrophy is unknown. However, all of these
pathways are associated with an increase in intracellular
Ca21, consistent with a central regulatory role of Ca21
in coordinating the activities of multiple hypertrophic
signaling pathways.
In B and T cells, the Ca21, calmodulin-dependent phos-
phatase calcineurin has been shown to link intracellular
signaling pathways that result in elevation of intracellular
Ca21 with activation of the immune response. Calcineu-
rin regulates immune response genes through dephos-
phorylation of a family of transcription factors known as
NF-ATs (nuclear factors of activated T cells) (reviewed in
Rao et al., 1997). Once dephosphorylated by calcineurin,
NF-AT transcription factors translocate to the nucleus
and directly activate immune response genes (Flanagan
et al., 1991; Loh et al., 1996a, 1996b). The immunosup-
pressant drugs cyclosporin A (CsA) and FK 506 sup-
press the immune response by inhibiting calcineurin's
ability to activate NF-AT transcription factors (Shaw et
al., 1995; Loh et al., 1996b).
Here we show that the myocardium utilizes a cal-
cineurin-dependent pathway to activate the transcrip- Figure 1. Interactions between GATA4 and NF-AT3 in the Two-
Hybrid Systemtion factor NF-AT3 during hypertrophy, suggesting a
conservation in signaling between immune cells and (A) Schematic diagrams of GATA4 and NF-AT3 proteins. The portion
of GATA4 used as bait in the two-hybrid system encompassedcardiomyocytes as a mechanism for responding to envi-
amino acids 130±409 and is shown beneath the full-length protein.ronmental stress. Our results show that activated cal-
The portion of NF-AT3 recovered in the yeast two-hybrid screencineurin is both necessary and sufficient to induce
spanned amino acids 522±902. The Rel homology domain (RHD)
cardiac hypertrophy in vitro and in vivo. Activation of extends from amino acids 404±694 and the conserved phosphoryla-
calcineurin results in dephosphorylation of NF-AT3 and tion domain from 145±275.
the subsequent induction of fetal cardiac genes via a (B) Amino acids 522±902 of NF-AT3 were fused in-frame to the GAL4
DNA-binding domain (DBD) and used as bait in a two-hybrid assaycombinatorial mechanism involving its direct interaction
in transfected 10T1/2 cells.with GATA4. Transgenic mice that express activated
forms of calcineurin or NF-AT3 in the heart develop
cardiac hypertrophy that progresses to dilated cardio-
for GATA4 in the heart. The GATA4 bait consisted ofmyopathy, with interstitial fibrosis, congestive heart
amino acids 130±409 fused in-frame to the yeast GAL4failure, and sudden death. CsA and FK 506 block the
protein (Figure 1A). This region of GATA4 encompassesmorphologic and molecular responses of primary car-
the two zinc fingers and most of the carboxyl terminusdiomyocytes to Ang II and PE, indicating that calcineurin
but lacks the amino-terminal transcription activation do-is a componentof the signalingpathways whereby these
main, and therefore does not activate transcription onfactors induce hypertrophy. Moreover, CsA administra-
its own in yeast. Screening of a 10.5-day mouse embryotion can prevent cardiac hypertrophy and associated
cDNA library resulted in the identification of numerouspathology in calcineurin transgenic mice. These results
GATA4-interacting factors, one of which was NF-AT3.define a novel signaling pathway that couples hypertro-
The other GATA4-interacting factors identified in thisphic signals at the cell membrane to changes in cardiac
screen will be described elsewhere.gene expression and suggest opportunities for pharma-
NF-AT3 is a member of a multigene family containingcologic intervention into cardiac hypertrophy and heart
four members, NF-ATc, NF-ATp, NF-AT3, and NF-AT4failure.
(McCaffrey et al., 1993; Northrop et al., 1994; Ho et al.,
1995; Hoey et al., 1995; Masuda et al., 1995; Park et al.,Results
1996). These factors bind the consensus DNA sequence
GGAAAAT as monomers or dimers through a Rel homol-Interaction between NF-AT3 and GATA4
ogy domain (RHD) (Rooney et al., 1994; Hoey et al.,Our initial interest was to identify proteins, using the
yeast two-hybrid system, that might act as cofactors 1995). Three of the NF-AT genes are restricted in their
Regulation of Cardiac Hypertrophy by Calcineurin
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Figure 2. Coimmunoprecipitation of GATA4 and NF-AT3
(A) NF-AT3 with a Flag epitope tag and GATA4, as indicated, were translated in a rabbit reticulocyte lysate in the presence of 35S-methionine.
Anti-Flag antibody was then used for coimmunoprecipitation assays. Proteins were resolved by SDS-PAGE. Lanes 1 and 2 show the in vitro
translation products. Lanes 3±5 show the coimmunoprecipitations. The anti-Flag antibody selectively immunoprecipitates NF-AT3 (lane 3) but
does not recognize GATA4 (lane 4). However, when NF-AT3 is mixed with GATA4, GATA4 is coimmunoprecipitated (asterisk in lane 5).
(B) The domain of GATA4 that interacts with NF-AT3 was mapped by translating NF-AT3-Flag with a series of GATA4 deletion mutants (shown
in [C]), followed by coimmunoprecipitation. Even-numbered lanes show the GATA4 or GATA6 (lane 14) deletion mutants loaded directly on
the gel. The other lanes contain the indicated GATA4 or GATA6 (lane 15) deletion mutants plus NF-AT3 and were immunoprecipitated with
anti-Flag antibody. All GATA4 deletion mutants except 80±441/d265±294, which lacks the second zinc finger, were coimmunoprecipitated. A
GATA6 deletion mutant containing the two zinc fingers was also coimmunoprecipitated with NF-AT3.
(C) Summary of coimmunoprecipitation results. F1 and F2 denote the two zinc fingers and NLS designates the nuclear localization signal.
(D) The C-terminal region of NF-AT3, encompassing the Rel homology domain (RHD), was translated separately or together with GATA4
deletion mutant 80±328, as indicated. Lanes 1 and 2 show the individual in vitro translation products loaded directly on the gel. Lanes 3±5
show the results of immunoprecipitation with anti-NFAT antibody that recognizes the NF-AT3 RHD. This region is sufficient for interaction
with GATA4 (indicated by an asterisk in lane 5).
expression to T cells and skeletal muscle, whereas NF- 1A). The region of NF-AT3 recovered from the yeast two-
hybrid screen extended from amino acid 522, which isAT3 is expressed in a variety of tissues including the
heart (Hoey et al., 1995). near the middle of the Rel homology domain, to the
carboxyl terminus.Given the ability of NF-AT factors to mediate changes
in gene expression in response to Ca21 signaling in T The specificity of interaction between GATA4 and NF-
AT3 was tested by retransforming yeastwith the rescuedcells, we were especially interested in the finding that
GATA4, a known effector of cardiac gene expression, NF-AT3-GAL4 activation domain plasmid and various
GAL4 DNA-binding domain bait plasmids. In this assay,and NF-AT3 were able to interact. This interaction sug-
gested a potential mechanism for coupling Ca21 signal- NF-AT3 was also found to interact with residues 133±265
of GATA5, which encompass only the zinc finger DNA-ing to cardiac transcription, as is known to occur during
cardiac hypertrophy. binding domain. However, NF-AT3 did not interact with
the basic helix-loop-helix protein E12 or with the GAL4NF-AT3 is a 902-amino acid protein with a regulatory
domain at its amino terminus that mediates nuclear DNA-binding domain alone (data not shown).
To validate further the interaction between GATA4translocation and the Rel homology domain near its
carboxyl terminus that mediates DNA binding (Figure and NF-AT3, the rescued NF-AT3 cDNA fragment was
Cell
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Figure 3. Regulation of the BNP Promoter by NF-AT3 in Primary Cardiomyocytes
(A) Primary rat cardiomyocytes were transiently transfected with a CAT reporter gene linked to the BNP 59-flanking region and expression
vectors encoding NF-AT3, activated calcineurin, or GATA4, as indicated. Forty-eight hours later, cells were harvested and CAT activity was
determined. In the lane labeled 2927 site mutant, a BNP-CAT reporter gene, in which the NF-AT3 site at 2927 was mutated, was used.
(B) 32P-labeled oligonucleotide probes corresponding to the potential NF-AT binding sites from the IL-2 promoter and from 2927, 2327, and
227 bp 59 of the BNP gene were used in gel mobility shift assays with unprogrammed reticulocyte lysate (lanes 1±4) or in vitro translated NF-
AT3 (lanes 5±8). Only the IL-2 and BNP-927 probes yielded a specific DNA±protein complex.
(C) A 32P-labeled oligonucleotide probe corresponding to the 2927 BNP site was used in gel mobility shift assays with protein extracts from
neonatal rat cardiomyocytes. Multiple specific complexes were generated (lane 1), which were competed by unlabeled cognate site (lane 2),
but not by an unrelated E-box oligonucleotide (lane 3). Addition of NF-AT3 antibody eliminated the major DNA±protein complex and created
a minor ternary complex (asterisk in lane 5), whereas nonimmune rabbit serum had no effect (lane 4). Free probe was electrophoresed off the
bottom of the gel in both experiments.
fused to the GAL4 DNA-binding domain and tested for the two zinc fingers and NLS, interacted with NF-AT3
as efficiently as full-length GATA4 (Figure 2B, lane 11).its ability to interact with full-length GATA4 in trans-
fected mammalian cells. As a reporter plasmid, we used Residues 239±441 of GATA4, which extend from the
secondzinc finger to the C terminus, also interacted withpG5E1bCAT, which contains five tandem GAL4 DNA-
binding sites upstream of the minimal E1b promoter NF-AT3 (lane 7), whereas an internal deletion mutant
lacking the second zinc finger (80±441/d265±294) didlinked to CAT. This reporter was not significantly acti-
vated by either GAL4-NF-AT3 or GATA4 alone but was not (lane 13). These experiments demonstrated that the
second zinc finger of GATA4 was essential for interac-strongly activated by the two factors together in 10T1/2
fibroblasts (Figure 1B), as well as in primary neonatal tion with NF-AT3, whereas the N terminus, the first zinc
finger, and the C terminus were unimportant for thisrat cardiomyocytes (data not shown). Full-length NF-
AT3 also interacted with the GAL4-GATA4 bait in the interaction (Figure 2C). Also of note, the zinc finger re-
gion (amino acids 130±350) of GATA6 was immunopre-mammalian transfection assay (data not shown).
cipitated with NF-AT3 (lane 15).
We also tested a deletion mutant of NF-AT3 thatMapping the Protein Determinants
of GATA4-NF-AT3 Interaction encompassed only the Rel homology domain, residues
404±694. This region was sufficient to interact withTo define further the interaction between GATA4 and
NF-AT3, we tested whether interactions between the GATA4 (Figure 2D, lane 5). Together, these results indi-
cated that the Rel homology region of NF-AT3 containedcorresponding 35S-methionine-labeled in vitro transla-
tion products could be detected. Cotranslation of full- determinants that mediate interaction with the second
zinc finger of GATA4.length GATA4 with the NF-AT3 deletion mutant con-
taining residues 522±902 fused to a Flag epitope at the
C terminus, followed by immunoprecipitation with anti- Synergistic Activation of the BNP Gene
by GATA4 and NF-AT3Flag antibody and SDS-PAGE, showed that the two pro-
teins coimmunoprecipitated (Figure 2A, lane 5). The anti- To begin to investigate whether the GATA4-NF-AT3 in-
teraction had a functional role in cardiac gene expres-Flag antibody did not immunoprecipitate GATA4 in the
absence of NF-AT3-Flag (lane 4). sion, we tested the ANF, BNP, and cardiac troponin I
promoters, which are up-regulated during hypertrophy,To map the determinants of this interaction more pre-
cisely, we tested a series of GATA4 deletion mutants for their responsiveness to these factors in transfected
neonatal rat cardiomyocytes. The BNP promoter showedfor the ability to be coimmunoprecipitated with NF-AT3-
Flag. Residues 181±328 of GATA4, which encompass a dramatic response and was therefore analyzed further.
Regulation of Cardiac Hypertrophy by Calcineurin
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Figure 4. Inhibition of AngII- and PE-Depen-
dent Hypertrophy of Primary Cardiocytes by
CsA and FK506
(A±F) Primary rat cardiocytes in serum-free
medium were stimulated with AngII (10 nM)
or PE (10 mM) for 72 hr. Cells were then fixed
and stained with anti-a-actinin antibody to
reveal sarcomeres and Hoechst stain to re-
vealnuclei. CsA (500 ng/ml) was added to one
set of cultures at the time of AngII addition.
(G) Total RNA was isolated from primary
cardiocyte cultures treated with AngII in the
presence or absence of CsA as in (A) and
analyzed for expression of GAPDH and ANF
transcripts by dot blot.
(H) Primary rat cardiomyocytes were tran-
siently transfected with an NF-AT-dependent
luciferase reporter gene. Cells were then
treated with AngII or PE in the presence or
absence of CsA, as described above. Forty-
eight hours later, cells were harvested and
luciferase activity was determined.
For these experiments, we also used a cDNA expression oligonucleotide probes corresponding to these se-
quences, we used gel mobility shift assays to test forplasmid encoding a constitutively active form of the
calcineurin catalytic A subunit lacking the C-terminal binding to in vitro translated NF-AT3 protein generated
in a rabbit reticulocyte lysate. The putative site at 2927autoinhibitory domain (O'Keefe et al., 1992). This cal-
cineurin mutant functions as a Ca21-independent phos- bound NF-AT3 as avidly as the consensus NF-AT site
from the IL-2 promoter, whereas no binding was de-phatase but retains sensitivity to CsA and FK506. As
shown in Figure 3A, the BNP promoter was activated tected to the 2327 or 227 sites (Figure 3B).
To confirm that NF-AT3 from cardiomyocytes couldgreater than 100-fold in the presence of GATA4, NF-
AT3, and calcineurin. GATA4 alone was also able to also bind the 2927 site from the BNP promoter, we used
cardiac protein extracts in a gel mobility shift assay withactivate this promoter, as reported previously (Grepin
et al., 1994), but the extent of activation was less than the 2927 site as a probe. Cardiac extract gave rise
to multiple complexes that could be eliminated in theone-tenth that when NF-AT3 and calcineurin were also
present. Since GATA4 and NF-AT3 are expressed in presence of an excessof thesame unlabeled oligonucle-
otide or by a sequence corresponding to the NF-ATneonatal rat cardiomyocytes, it seems they are limiting
in this type of transfection assay, making it necessary site in the IL-2 promoter (data not shown), but not by
nonspecific sequences (Figure 3C). The cardiomyocyteto express the exogenous proteins to see the maximal
response of the BNP promoter. complex could also be largely eliminated using an NF-
AT3-specific antibody (lane 5).Given the dramatic responsiveness of the BNP pro-
moter to NF-AT3, we examined the 1800 bp promoter To determine whether the 2927 site was required for
transcriptional activation by NF-AT3, we mutated thisregion used in the above transfection assays for po-
tential NF-AT consensus binding sites (GGAAAAT). Three site and found that the mutant promoter was insensitive
to NF-AT3 (Figure 3A). These results demonstrate thatsequences related to this site were identified at 2927
(TGGAAAACAA), 2327 (TGGAAAAGGC), and 227 (AGG the BNP promoter is a direct transcriptional target for
synergistic activation by GATA4 and NF-AT3 in cardio-ATAAAAG). The 227 site also binds GATA4 and is re-
quired for BNP expression (Grepin et al., 1994). Using myocytes.
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Table 1. Summary of a-MHC-Calcineurin Transgenic Lines
Transgenic Line Transgene Copy # Cause of Death Age at Death Heart Weight Tg./Control Cardiac Phenotype
46 8 Sacrificed 18 days 2.2 Hypertrophic
22 22 Sudden 10 weeks 2.3 Dilated
110 3 Sudden 4 weeks 2.6 Hypertrophic
106 2 Sudden 9 weeks ND ND
108 3 Still alive (14 weeks) Ð Ð
41 68 Still alive (24 weeks) Ð Ð
37 15 Still alive (23 weeks) Ð Ð
37-1 15 Sacrificed 5 weeks 2.3 Hypertrophic
37-2 15 Sudden 4 weeks ND Hypertrophic
37-3 15 Sudden 3 weeks 2.5 Hypertrophic
37-4 15 Still alive (8 weeks) Ð Ð
37-5 15 Still alive (8 weeks) Ð Ð
37-6 15 Sudden 12 weeks 2.9 Dilated
39 3 Sudden 11 weeks 2.7 Hypertrophic
39-1 3 Sudden 3 weeks ND Hypertrophic
39-2 3 Sudden 4 weeks ND ND
39-3 3 Still alive (10 weeks) Ð Ð
Heart weights were determined and are expressed as the relative weight of the transgenic heart compared to nontransgenic litter mates.
Ages of mice that are still alive are shown in parentheses as of 2/18/98. 37 and 39 were founder transgenics and, mice designated as 37-
and 39- were their offspring. ND, not determined.
CsA and FK506 Inhibit the Hypertrophic Induction of Cardiac Hypertrophy In Vivo
Effects of AngII and PE by Activated Calcineurin
Exposure of primary cardiomyocytes to AngII and PE To determine whether the calcineurin signal transduc-
results inan increase in intracellular Ca21 and a hypertro- tion pathway could also operate in the myocardium in
phic response. To determine whether the hypertrophic vivo, we generated transgenic mice that expressed the
response of cardiomyocytes to these agonists was me- constitutively active form of the calcineurin catalytic
diated by calcineurin, we exposed neonatal rat cardio- subunit in the heart, using the a-MHC promoter to drive
myocytes to AngII (10 nM) or PE (10 mM) in the presence expression. Previous studies have shown that this car-
and absence of CsA or FK 506. Cardiomyocytes demon- diac-specific promoter is active in the ventricular cham-
strated a dramatic increase in size and sarcomeric as- bers primarily after birth (Jones et al., 1994). A totalof ten
sembly after 72 hr of exposure to AngII or PE (Figures independent founder transgenic mice were generated,
4B and 4E). In the presence of CsA (Figures 4C and 4F) which containedbetween 2 and 68 copies of the a-MHC-
or FK 506 (data not shown), the response to AngII was calcineurin transgene (Table 1).
completely abolished and the response to PE was dra- Every calcineurin transgenic mouse analyzed showed
matically reduced. a dramatic increase in heart size relative to nontrans-
To determine whether changes in cardiomyocyte gene genic littermates. The heart-to-body weight ratio aver-
expression in response to AngII were also controlled by aged 2- to 3-fold greater in the calcineurin transgenics
a calcineurin-dependent signaling pathway, we exam- compared to control littermates, even as early as 18
ined by dot blot assay the expression of ANF mRNA in days postnatally (Figure 5, Table 1). Histological analysis
cardiomyocytes treated with AngII in the presence and
showed concentric hypertrophy wherein the cross sec-
absence of CsA. Exposure to AngII resulted in a 15-fold
tional areas of the ventricular walls and interventricular
increase in ANF mRNA, which was completely blocked
septum were dramatically increased (Figure 5C). Theby CsA (Figure 4G). GAPDH mRNA was measured as a
left ventricle was most affected, but the right ventriclecontrol. Together, these morphologic and molecular
and the atrial chambers were also enlarged. In contrastdata demonstrate that the AngII and PE hypertrophic
to the well-organized, striated musculature of the normalsignaling pathways are CsA-/FK 506-sensitive and there-
ventricular wall, cardiomyocytes from the calcineurinfore involve calcineurin activation.
transgenic hearts were disorganized and obviously hy-If NF-AT activation mediates Ca21-dependent hyper-
pertrophic (Figures5D and 5E). The hypertrophic cardio-trophic signaling, then AngII and PE would be expected
myocytes often had dramatic karyomegaly. Measure-to induce NF-AT activity. To test this, we transfected
ment of cross sectional areas of myocytes within the leftprimary rat cardiomyocytes with an NF-AT-dependent
ventricular wall showed a greater than 2-fold increase inluciferase reporter containing three copies of the NF-
calcineurin transgenics compared to controls (data notAT consensus sequence linked to the thymidine kinase
shown).minimal promoter. In the presence of AngII (10 nM) or
In humans, cardiac hypertrophy frequently progressesPE (10 mM), reporter gene expression was up-regulated
to ventricular dilatation, heart failure, and sudden death.(Figure 4H). This up-regulation was completely abol-
Similarly, in calcineurin transgenic mice, we observedished in the presence of CsA or FK 506, supporting the
dilatation of the ventricular chambers with increasingconclusion that AngII and PE activate NF-AT through a
calcineurin-dependent signal transduction pathway. age (Figures 5F and 5G). Calcineurin transgenic mice
Regulation of Cardiac Hypertrophy by Calcineurin
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Figure 5. Hypertrophy of a-MHC-Calcineurin
Transgenic Hearts
(A) Control and a-MHC-calcineurin trans-
genic littermates were sacrificed at 18 days
of age and hearts were removed and photo-
graphed. (B and C) Hearts shown in (A) were
sectioned longitudinally. The left ventricular
wall and septum are extensively hypertro-
phied in the calcineurin transgenic (C). (D and
E) High magnification views of left ventricular
walls of hearts shown in (B) and (C), respec-
tively. (F and G) Transverse sections through
hearts of control and calcineurin transgenics
at 9 weeks of age stained with H and E. The
calcineurin transgenic died suddenly and
shows hypertrophy and dilatation. (H) Sec-
tions from the calcineurin transgenic heart
shown in (G) were stained with Masson tri-
chrome to reveal collagen. Note the extensive
interstitial collagen deposits surrounding de-
generated cardiomyocytes. Ca, coronary ar-
tery; la, left atrium; lv, left ventricle; ra, right
atrium; rv, right ventricle. Bars in (B), (C), (F),
(G), and (H) 5 1 mm. Bars in (D) and (E) 5
50 mm.
were also highly susceptible to sudden death. This oc- down-regulated during heart failure, as the failing myo-
cardium exhibits defective Ca21 handling (Schwinger etcurred spontaneously, as well as during handling or an-
esthesia. The mice that died from sudden death showed al., 1995); both transcripts were decreased in calcineurin
transgenics. There was no significant change in GAPDHright and left ventricular dilatation indicative of heart
failure. Histology of the lungs also revealed extensive expression.
perivascular edema and intraalveolar macrophages con-
taining red blood cells (data not shown), findings consis- Induction of Cardiac Hypertrophy In Vivo
tent with heart failure. One of the hallmarks of heart by Activated NF-AT3
failure is fibrosis of the ventricular wall. The hearts of While activation of NF-AT3 proteins is a well-character-
calcineurin transgenics contained extensive, primarily ized mechanism of action of calcineurin in T cells, and
interstitial, deposits of collagen, as revealed by tri- NF-AT was able tosynergize with GATA4 and calcineurin
chrome staining (Figure 5H). In foci with marked fibrosis, to activate the BNP promoter in cultured cardiomyo-
myofiber degeneration was evident. cytes, it was formally possible that the hypertrophic
response to calcineurin in vivo could involve a NF-AT-
independent mechanism. To determine whether acti-Activation of the Molecular Response to
Hypertrophy In Vivo by Calcineurin vated NF-AT3 could substitute for all upstream elements
in the hypertrophic signaling cascade, we created aWe used a quantitative dot blot assay to examine RNA
from hearts of calcineurin transgenic and nontransgenic constitutively active NF-AT3 mutant by deleting the
N-terminal regulatory domain. This mutant, referred tolittermates to determine whether activated calcineurin
induced changes in cardiac gene expression character- as NF-AT3D317, lacked the first 317 amino acids of the
protein but retained the Rel homology and transactiva-istic of hypertrophy and heart failure. Consistent with
reactivation of the fetal program of gene expression, tion domains (Figure 7A).
When NF-AT3D317 was expressed in transfected car-b-MHC, a-skeletal actin, and BNP transcripts were dra-
matically up-regulated in transgenic hearts, whereas diomyocytes, it became constitutively localized to the
nucleus, in contrast to the wild-type protein, which re-a-MHC was down-regulated (Figure 6). Transcripts for
sarcoplasmic reticulum Ca21-ATPase (SERCA) and phos- quired calcineurin signaling for nuclear localization (Fig-
ures 7B and 7C). The NF-AT3D317 mutant also activatedpholamban (PLB) have been shown previously to be
Cell
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Figure 6. Changes in Cardiac Gene Expression in a-MHC-Cal-
cineurin Transgenic Mice
Total RNA was isolated from hearts of control and a-MHC-cal-
cineurin transgenic mice at 6 weeks of age. The indicated transcripts
were detected by dot blot analysis, and their levels in transgenic
hearts relative to controls are shown.
the NF-AT-dependent reporter construct in transient
transfection assays (data not shown). We therefore ex-
pressed this mutant in the hearts of transgenic mice,
under control of the a-MHC promoter. Three indepen-
dent founder transgenic mice were obtained, and all
showed pronounced left and right ventricular concentric
hypertrophy (Figures 7D and 7E). Like the calcineurin
transgenics, the ventricular walls of the NF-AT3D317
transgenics showed extensive fibrosis, with myofiber
disarray and cardiomyocyte enlargement. In contrast,
Figure 7. Hypertrophy of a-MHC-NF-AT3 Transgenic Hearts
expression of wild-type NF-AT3 under control of the
(A) Structure of NF-AT3 and NF-AT3D317 mutant. RHD, Rel homol-
a-MHC promoter did not lead to hypertrophy (data not ogy domain; Reg, regulatory domain. Amino acid positions are indi-
shown). Thus, activated NF-AT3 alone is sufficient to cated.
substitute for Ca21 signals in the heart and evoke a (B and C) Primary cardiomyocytes were transfected with full-length
NF-AT3 and NF-AT3D317 mutant cDNAs, respectively, and cellshypertrophic response in vivo.
were stained with anti-NF-AT antibody. NF-AT3 is localized to the
cytoplasm whereas NF-AT3D317 is localized to the nucleus.Prevention of Cardiac Hypertrophy with CsA
(D and E) Hearts from nontransgenic and NF-AT3D317 littermatesTo begin to determine whether inhibition of calcineurin
at 4 weeks of age were sectioned longitudinally and stained with H
activity in vivo might be an effective means of preventing and E. La, left atrium; lv, left ventricle; ra, right atrium; rv, right
cardiac hypertrophy, we tested whether subcutaneous ventricle. Bars in (D) and (E) 5 2 mm.
injection of CsA could prevent cardiac dysfunction in
calcineurin transgenic mice. For these experiments, we
myofiber disarray and scattered cells with prominentused eight transgenic littermates from a litter of trans-
hyperchromatic nuclei. Whether these represent cellsgenic mouse #37 (see Table 1). Four transgene-positive
that were already hypertrophic at the time CsA adminis-offspring were injected twice daily with CsA (25 mg/kg
tration was initiated or whether there are a few cells thatbody weight) and four were injected with vehicle alone.
escaped the effects of CsA will require further investiga-Four nontransgenic littermates were also treated with
tion. Nevertheless, CsA treatment prevented gross car-CsA to control for potential toxic effects or cardiac ab-
diac hypertrophy and associated pathology in responsenormalities induced by CsA. CsA treatment was initiated
to activated calcineurin in vivo.at 9 days of age and animals were sacrificed 16 days
later. As shown in Figure 8, the hearts of vehicle-treated
Discussionanimals were highly hypertrophic and dilated by day 25,
whereas those from CsA-treated littermates were not
Our results define an intracellular pathway for inductionsignificantly different in size from nontransgenic con-
of cardiac hypertrophy that links Ca21 signaling in thetrols. The mean heart-to-body weight ratios for cal-
cytoplasm with changes in cardiac gene expression.cineurin transgenics were nearly 3-fold larger than those
Activation of this hypertrophic pathway either in theof CsA-treated transgenics and nontransgenics. CsA
cytoplasm or in the nucleus, with activated forms oftreatment also prevented fibrosis of the hearts of cal-
calcineurin or NF-AT3, respectively, results in molecularcineurin transgenics (data not shown).
and pathophysiologic changes in the hearts of trans-At a cellular level, the hypertrophic response of cardio-
genic mice that mimic those associated with cardiacmyocytes in the calcineurin transgenics was largely in-
hibited by CsA, although there were isolated areas of hypertrophy and heart failure in humans.
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Figure 8. Prevention of Calcineurin-Dependent Hypertrophy by CsA
(A) The regimen for CsA treatment is shown.
(B) a-MHC-calcineurin transgenic (TG) and nontransgenic mice were treated with or without CsA (25 mg/kg body weight), as indicated. Heart-
to-body weight ratios are expressed 6 standard deviations. Transgenic littermates obtained from male calcineurin transgenic #37 (see Table
1) were injected subcutaneously twice daily with CsA or vehicle alone beginning at 9 days of age. At 25 days of age, animals were sacrificed
and hearts were removed and sectioned longitudinally.
(C) H and E sections of hearts from nontransgenic (control) and transgenic mice treated with vehicle (center panel) or CsA (right panel). La,
left atrium; lv, left ventricle; ra, right atrium; rv, right ventricle. The right atrium was removed from the control, and both atria were removed
from the transgenic treated with CsA. Bar 5 2 mm.
Calcineurin, a Ca21-Sensitive Regulator mediator of cardiac hypertrophy in response to cal-
cineurin activation. (1) NF-AT activity was induced byof Hypertrophy
It is well established that elevation in intracellular Ca21 treatment of cardiomyocytes with AngII and PE. This
induction was blocked by CsA and FK 506, indicatingis associated with the initiation of mechanical or agonist-
induced cardiac hypertrophy (Marban et al., 1987; Bus- that it is calcineurin-dependent. (2) NF-AT3 synergized
with GATA4 to activate the BNP promoter in cardiomyo-tamante et al., 1991; Le Guennec et al., 1991; Saeki et
al., 1993; Peurreault et al., 1994; Hongo et al., 1995). cytes. (3) Expression of activated NF-AT3 in the heart
was sufficient to bypass all upstream elements in theRemarkably, however, the possibility that calcineurin
might participate in the transduction of hypertrophic hypertrophic signaling pathway and evoke a hypertro-
phic response.signals in cardiomyocytes has not been addressed.
Calcineurin is a ubiquitously expressed serine/threo-
nine phosphatase that exists as a heterodimer, com- Combinatorial Interactions between GATA
and NF-AT Proteinsprised of a 59 kDa calmodulin-binding catalytic A sub-
unit and a 19 kDa Ca21-binding regulatory B subunit Our results demonstrate that the C-terminal portion of
the Rel homology domain of NF-AT3 interacts with the(Stemmer and Klee, 1994; Su et al., 1995). Calcineurin
is uniquely suitedto mediate the prolongedhypertrophic second zinc finger of GATA4, as well as with GATA5
and GATA6, which are also expressed in the heart. Theresponse of a cardiomyocyte to Ca21 signaling because
the enzyme is activated by a sustained Ca21 plateau crystal structure of the DNA binding region of NF-ATc
has revealed that the C-terminal portion of the Rel ho-and is insensitive to transient Ca21 fluxes such as occur
in response to cardiomyocyte contraction (Dolmetsch mology domain projects away from the DNA-binding
site and also mediates interaction with AP-1 in immuneet al., 1997).
Activation of calcineurin is mediated by binding of cells (Wolfe et al., 1997).
What is thesignificance of theNF-AT3-GATA4 interac-Ca21 and calmodulin to the regulatory and catalytic sub-
units, respectively. Previous studies showed that over- tion for activation of the hypertrophic response? Coop-
erative activation of the BNP promoter by NF-AT3 andexpression of calmodulin in the heart also results in
hypertrophy, but the mechanism involved was not deter- GATA4 requires NF-AT binding to a target sequence in
the BNP upstream region. Previous studies have dem-mined (Gruver et al., 1993). Our results suggest that
calmodulin acts through the calcineurin pathway to in- onstrated that GATA4 binding sites located near the
proximal BNP promoter are also required for activationduce the hypertrophic response.
In T cells, many of the changes in gene expression of the gene (Grepin et al., 1994). Thus, on this specific
hypertrophic-responsive gene, and perhaps others, thesein response to calcineurin activation are mediated by
members of the NF-AT family of transcription factors, factors act combinatorially to activate transcription. NF-
AT proteins regulate certain T cell genes by binding awhich translocate to the nucleus following dephosphor-
ylation by calcineurin. Three independent observations composite DNA sequence in conjunction with AP-1
(Wolfe et al., 1997). In the case of the BNP promoter,support the conclusion that NF-AT is also an important
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we have no evidence for this type of joint DNA binding
between GATA4 and NF-AT3, since the binding sites for
these factors are not immediately adjacent and sites
for both factors are required for synergistic activation.
Moreover, in DNA binding assays, we have found no
evidence for binding of GATA4 and NF-AT3 together to
either type of site (data not shown).
A variety of transcription factors have been implicated
in cardiac hypertrophy, including TEF-1 (Kariya et al.,
1994; Karns et al., 1995), SRF (Sadoshima and Izumo,
1993; Sadoshima et al., 1993), AP-1 (Kovacic-Milivojevic
et al., 1996), and GATA4 (Hasegawa et al., 1997; Herzig
et al., 1997). In light of the cooperation between NF-AT
and AP-1 in the control of T cell gene expression, it is
tempting to speculate that a similar mechanism could
regulate certain cardiac genes in response to hypertro- Figure 9. A Model for the Calcineurin-Dependent Transcriptional
Pathway in Cardiac Hypertrophyphy. Whether NF-AT interacts with or regulates the ex-
AngII, PE, and possibly other hypertrophic stimuli acting at the cellpression of other transcription factors that control car-
membrane lead to elevation of intracellular Ca21 and activation ofdiac genes warrants further investigation.
calcineurin in the cytoplasm. Calcineurin dephosphorylates NF-AT3,Six GATA transcription factors have been identified
resulting in its translocation to the nucleus, where it interacts with
in vertebrate species, each of which contains a highly GATA4 to synergistically activate transcription. Whether all actions
conserved DNA-binding domain consisting of two zinc of NF-AT3 are mediated by its interaction with GATA4 or whether
fingers of the motif Cys-X2-Cys-X17-Cys-X2-Cys (reviewed there are GATA4-independent pathways for activation of certain
hypertrophic responses remains to be determined. Solid arrowsin Evans, 1997). Based on sequence homology and ex-
denote pathways that are known. Dotted lines denote possible path-pression patterns, the GATA proteins can be divided
ways that have not been demonstrated.into two subfamilies. GATA1/2/3 are expressed in hema-
topoietic cells, while GATA4/5/6 are expressed primarily
in the heart and vascular system, as well as in vis-
pathways (Sadoshima and Izumo, 1993; Sadoshima etceral endodermal derivatives. Given the importance of
al., 1993; Zou et al., 1996; Kudoh et al., 1997; YamazakiGATA1/2/3 in hematopoietic cells and the well-docu-
et al., 1997). CsA does not interfere with early signalingmented roles of NF-AT proteins in T cells, it will be
events at the cell membrane, such as PI turnover, Ca21of interest to determine whether these two families of
mobilization, or PKC activation (Emmel et al., 1989).transcription factors can interact in these cells.
Thus, its ability to abrogate the hypertrophic responses
of AngII and PE suggests that calcineurin activation isA Transcriptional Pathway for Cardiac Hypertrophy
an essential step in the AngII and PE signal transductionPrevious studies have demonstrated important roles for
pathways.Ras, MAP kinase, and PKC signaling pathways in the
Our results are consistent with a molecular pathwayhypertrophic response. All of these signal transduction
for cardiac hypertrophy as shown in Figure 9. Accordingpathways are associated with an inotropic increase in
to this model, hypertrophic stimuli such as AngII andintracellular Ca21 concentration. In T cells, the calcineu-
PE, which lead to an elevation of intracellular Ca21, resultrin signaling pathway is activated independently of, but
in activation of calcineurin. NF-AT3 within the cytoplasmis integrated with, the Ras/MAP kinase and PKC path-
is dephosphorylated by calcineurin, enabling it to trans-ways. Full induction of IL-2 transcription requires co-
locate to the nucleus where it can interact with GATA4.stimulation via the calcineurin and Ras pathways, which
While calcineurin is essential for AngII- and PE-depen-result in activation of NF-AT and AP-1, respectively,
dent hypertrophy in vitro, and activation of either cal-and their convergence on a common downstream target
cineurin or NF-AT3 is sufficient to evoke the hyper-sequence (reviewed in Rao et al., 1997). This type of
trophic response in vivo, it is also conceivable thatintegrated signaling bears obvious similarities to the
calcineurin could act through an NF-AT-independentmechanisms for induction of cardiac hypertrophy. While
mechanism to regulate hypertrophy. Indeed, calcineu-our results demonstrate that the calcineurin-NFAT3 sig-
rin could potentially have other substrates in cardio-naling pathway is sufficient to induce hypertrophy in
myocytes that play regulatory roles in Ca21 handling orvivo, it also seems likely that this pathway and the Ras/
transcriptional control. NF-AT3 could also potentiallyMAP kinase pathway may be interdependent in cardio-
activate some hypertrophic responsive genes, throughmyocytes, as in immune cells.
mechanisms independent of GATA4. This model alsoCsA and FK 506 bind the immunophilins cyclophilin
predicts that phosphorylation of the N-terminal regula-and FK 506±binding protein (FKBP12), respectively,
tory sites in NF-AT3 could be a key regulatory step informing complexes that bind the calcineurin catalytic
the hypertrophic signaling pathway. By inference, acti-subunit and inhibit its activity. Our results show that
vation of the NF-AT kinase would be expected to inter-CsA and FK 506 block the ability of cultured cardiomyo-
fere with hypertrophy, whereas its inhibition would leadcytes to undergo hypertrophy in response to AngII and
to hypertrophy.PE. Both of these hypertrophic agonists have been
These studies also raise the possibility that an NF-shown to act by elevating intracellular Ca21, which re-
sults in activation of the PKC and MAP kinase signaling AT-dependent mechanism could control normal cardiac
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clones (approximately 21) were retransformed back into yeast togrowth during development. In this regard, NF-AT3 is
test for specificity.Three separate criteria were set for determinationexpressed in cardiomyocytes within the embryonic heart
of specificity. First, the isolated clones had to recapitulate the inter-(J. D. M. and E. N. O., unpublished data).
action. Second, the isolated clones could not interact with a nonspe-
cific bait, in this case a GAL4-E12 fusion. Third, we chose to focus
Calcineurin and NF-AT3 Transgenic Mice initially on factors that could also interact with GATA5, since there
is greater than 92% amino acid conservation within the zinc fingeras Models for Dilated Cardiomyopathy
domains of GATA4 and GATA5. The NF-AT3 prey clone fulfilledand Heart Failure in Humans
these criteria.The results of this study raise the possibility that calci-
The rescued NF-AT3 cDNA fragment was also subcloned as aneurin activation may regulate hypertrophy in response
XhoI fragment into the SalI site of the mammalian GAL4 fusion
to a variety of pathologic stimuli and suggest a sensing plasmid pM1 and tested for activation of the GAL4-dependent re-
mechanism for altered sarcomeric function. Of note, porter. Methods for culturing and transfection of 10T1/2 cells along
with the analysis of CAT activity were described previously (Molken-there are several familial hypertrophic cardiomyopathies
tin et al., 1996).(FHC) caused by mutations in contractile protein genes,
which result in subtle disorganization in the fine crystal-
In Vitro Translation and Immunoprecipitationline-like structure of the sarcomere (Watkins et al., 1995;
The partial NF-AT3 cDNA region rescued from the two-hybrid prey
Vikstrom and Leinwand, 1996). It is unknown how sarco- plasmid was subcloned as an XhoI fragment into the SalI site of
meric disorganization is sensed by the cardiomyocyte, the pECE-Flag mammalian expression vector. To generate a vector
but it is apparent that this leads to altered Ca21 handling suitable for in vitro translation, the NF-AT3 cDNA fragment along
with the 59 Flag epitope was excised from pECE-Flag-NF-AT3 as(Lin et al., 1996; Botinelli et al., 1997; Palmiter and Solaro,
a NotI-XbaI fragment and cloned into the pCite2B T7 promoter-1997). Calcineurin could represent the sensing molecule
containing in vitro transcription vector (Invitrogen). This allowed forthat couples altered Ca21 handling associated with FHC
the generation of a 387 amino acid NF-AT3-Flag fusion protein. SalI-
with cardiac hypertrophy and heart failure. XbaI fragments corresponding to the denoted amino acids in GATA4
The a-MHC-calcineurin transgenic mice also represent were subcloned to generate pCite2A-GATA4 80±441, pCite2A-
a model in which to investigate the potential reversibility GATA4 181±441, pCite2A-GATA4 239±441, pCite2A-GATA4 80±328,
pCite-GATA4 181±328, and pCite2A 80±441/d265±294. A cDNAfrag-of cardiac hypertrophy and the architectural changes
ment encoding amino acids 130±350 of mouse GATA6 was alsoassociated with heart failure because the hypertrophic
cloned as a SalI-XbaI fragment into pCite2A. In addition, a T7 pro-effector molecule can be inhibited pharmacologically.
moter-directed construct encoding the entire Rel homology domain
Since these mice ultimately progress to dilated cardio- of the human NF-AT3 protein (amino acids 404±694) was used in
myopathy, treatment with CsA at these later stages will these studies (gift from Dr. T. Hoey) (Hoey et al., 1995).
suggest the degree to which pathological conditions Coupled in vitro transcription and translation from the T7 promoter
was performed in the presence of 35S-methionine according to theand structural alterations associated with the hypertro-
TNT kit protocol (Promega, Madison, WI). Immunoprecipitationsphic response are reversible.
were directed against the Flag epitope using Flag antibody (KodakThese results also raise the question whether CsA
IBI, New Haven, CT) (Figures 2A and 2B) or against the Rel homology
or FK506 might be useful in the treatment of cardiac domain of NF-AT3 (antibody described in Lyakh et al., 1997) (Figure
hypertrophy and heart failure inhumans. These immuno- 2D). In vitro transcription-translation was performed in a reaction
suppressants are used routinely in transplant patients volume of 25 ml with 0.5 mg of each construct. Five microliters of
this reaction mix was immunoprecipitated according to the manu-to prevent tissue rejection, but clinical data correlating
facturer's recommended conditions (Kodak IBI, New Haven, CT) inCsA treatment with cardiac function in transplant pa-
a total volume of 100 ml with 2 ml of anti-FLAG monoclonal antibody,tients are inconclusive (Haverich et al., 1994). However,
or 5 ml of NF-AT3-specific antibody together with 25 ml of protein-
it has been reported in a study of heart transplant pa- A/G agarose. The precipitated products were analyzed by SDS-
tients that CsA increases cardiac function and left ven- PAGE and autoradiography.
tricular ejection fraction and results in fewer ischemic
episodes (Reid and Yacoub, 1988). Given the remarkable Preparation of Primary Rat Cardiomyocytes
Cardiomyocyte cultures were prepared by dissociation of 1-day-similarity between the molecular and pathophysiologi-
old neonatal rat hearts and were differentially plated to removecal responses of the heart in calcineurin transgenic
fibroblasts. To induce the hypertrophic response, AngII and PE weremice and in human heart failure, these transgenic mice
added to cardiomyocyte cultures at 10 nM and 10 mM, respectively,
should be a useful model for drug discovery and for in serum-free M199 media. The culture media containing either ago-
identifying additional genes that influence the hypertro- nist was changed every 12 hr for a period of 72 hr. CsA and FK 506
phic response. were present at 500 ng/ml and 150 ng/ml, respectively, over the
entire 72 hr culturing period. To analyze effects of these agents on
NF-AT3 activity, an NF-AT-dependent reporter was transfected intoExperimental Procedures
cardiomyocytes by Ca21 phosphate transfection in M199 serum-
free media. Cardiomyocytes were then cultured for 72 hr with theTwo-Hybrid Screens
identified agent.The NF-AT-dependent reporter contained three NF-The GATA4 bait used for the yeast two-hybrid screen contained
AT binding sites from the IL-2 promoter cloned upstream of theamino acids 130±409 fused in-frame with the GAL4 DNA-binding
thymidine kinase minimal promoter andthe luciferase gene (gift fromdomain. This region of GATA4 encompasses the two zinc finger
T. Hoey). Methods of preparation for cellular extracts and luciferasedomains and was encoded within a PstI-NsiI fragment, which was
assays have been described (Molkentin et al., 1994).cloned into a Pst I site in the pAS yeast expression vector. pAS-
GATA4 was cotransformed into yeast with an embryonic 10.5mouse
cDNA library that contained the GAL4 activation domain fused to Gel Mobility Shift Assays and Mutagenesis
To identify potential NF-AT binding sites within the BNP promoter,random cDNAs. From over 5 million primary colonies screened,
approximately 100 positive colonies were identified. From each indi- gel mobility shift assays were performed with double-stranded oli-
gonucleotides corresponding to putative sites located at 2927,vidual colony, the activating plasmid was rescued and the cDNA
insert was sequenced. Clones containing cDNA inserts in the anti- 2327, and 227, relative to the transcription start site (Owaga et al.,
1995), or the consensus site from the IL-2 promoter. Sequences ofsense orientation or out-of-frame were discarded. The remaining
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